CytomX Therapeutics, Inc. (CTMX) financial statements (2020 and earlier)

Company profile

Business Address 151 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:326436374182187
Cash and cash equivalents16524817810560
Short-term investments16118919777127
Other undisclosed cash, cash equivalents, and short-term investments   (0)(0)
Receivables001021
Other undisclosed current assets99442
Total current assets:335445389188190
Noncurrent Assets
Operating lease, right-of-use asset26
Property, plant and equipment77443
Intangible assets, net (including goodwill)22333
Goodwill11111
Intangible assets, net (excluding goodwill)11222
Restricted cash and investments11111
Other noncurrent assets11130
Total noncurrent assets:38129117
TOTAL ASSETS:373457398199197
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2545211510
Accounts payable55475
Accrued liabilities20271695
Taxes payable 13   
Deferred revenue51
Deferred revenue and credits41206
Contract with customer, liability53
Total current liabilities:7698613616
Noncurrent Liabilities
Long-term debt and lease obligation26    
Operating lease, liability26
Liabilities, other than long-term debt1892282678555
Deferred revenue and credits2658455
Deferred revenue188
Contract with customer, liability225
Deferred tax liabilities, net  11
Other liabilities13210
Total noncurrent liabilities:2142282678555
Total liabilities:29032632812171
Stockholders' equity
Stockholders' equity attributable to parent, including:821317078126
Common stock00000
Additional paid in capital464446289255244
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)
Accumulated deficit(382)(315)(219)(176)(117)
Other undisclosed stockholders' equity attributable to parent    (0)
Total stockholders' equity:821317078126
TOTAL LIABILITIES AND EQUITY:373457398199197

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net7215 
Gross profit:616072158
Operating expenses(160)(137)(118)(75)(41)
Operating loss:(99)(78)(46)(60)(33)
Nonoperating income (expense)9832(0)
Investment income, nonoperating98321
Other nonoperating expense(0)(0)(0)(0)(2)
Interest and debt expense   (2)(2)
Loss from continuing operations before income taxes:(90)(70)(44)(59)(35)
Income tax expense (benefit)(9)(14)10(0)
Net loss attributable to parent:(99)(85)(43)(59)(35)
Preferred stock dividends and other adjustments    (7)
Net loss available to common stockholders, diluted:(99)(85)(43)(59)(42)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(99)(85)(43)(59)(35)
Other comprehensive income (loss) 0(0)0(0)
Other undisclosed comprehensive income0    
Comprehensive loss:(99)(85)(43)(59)(35)
Other undisclosed comprehensive income, net of tax, attributable to parent0    
Comprehensive loss, net of tax, attributable to parent:(99)(85)(43)(59)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: